3 personalized medicine stocks to buy for long-term returns

Medicine is not always simple. A drug that cures one patient can easily kill another based on the patient’s weight, genetics, etc. Therefore, doctors should always be vigilant and know as much as possible about the patient before giving aggressive treatment. Therefore, personalized medicine stocks have become very important for investors to understand.

Personalized medicine promises to provide the best possible care for every patient. If you know everything there is to know about your patient’s health condition, you can tailor treatment to cure them most quickly and efficiently. Treatment may not work for everyone. In fact, it may not work for anyone but this patient. But if that cures it, well, I won’t complain.

But to achieve this, companies need vast amounts of data about their patients. In addition, these companies also need to know a lot about their drugs. For this reason, personalized medicine is often done in conjunction with big data.

For companies that can achieve this, personalized medicine is expected to be the future of healthcare. These promise that everyone will have personalized care, increased patient satisfaction and more money. Here are the top 3 personalized medicine companies to invest in in 2023.

EXAS precision science $79.19
GSKMore GSK PLC $36.53
ADPTMore Adaptive biotechnology $6.46

Exact Science (EXAS)

OLK stock. Modern medical laboratory: his two scientists wearing face masks use microscopes, analyze samples in petri dishes and talk. Advanced scientific research institute for medicine and biotechnology. Blue.  KZR stock. RSLS stock

Source: Gorodenkov / Shutterstock.com

All cancers are slightly different. Some cancers are caused by mitochondrial dysfunction. Some are caused by her DNA damage pathway. Others are driven by cell signaling pathways. Treating specific factors in a patient’s cancer may lead to better outcomes than broad, non-specific treatment.

that’s the promise behind it precision science (Nasdaq:EXAS) and a battery of cancer tests. These diagnoses allow doctors to prescribe precise treatments for patients rather than forcing cancer to be treated with a broad range of generally applicable treatments. Exact Sciences tests allow doctors to read the DNA and RNA of cancer cells to determine how they work and which drugs work best. In particular, the recently released OncoExTra provides comprehensive genetic profiling of patient cancers.

Exact has shown that there is a deep market for their testing. The company’s most recent earnings report shows a 25% increase in revenue from Q1 2022 to Q1 2023. The company has also raised its earnings outlook and expects to be cash flow positive in 2023. Future growth seems assured as an aging population simply means more people. Cancer to be treated.

Many of the latest anticancer drugs are indicated only for specific subtypes of cancer, ie cancers with specific mutations. To use these drugs, doctors first need to test whether the patient’s cancer actually carries the mutation. For that, you’ll need to rely on gene profiling services like the one offered by Exact. Exact is well positioned for continued growth in precision medicine services, making it one of the best personalized medicine stocks to buy now.


GlaxoSmithKline (GSK) office in London.

Source: Willie Burton/Shutterstock.com

GSK PLC (New York Stock Exchange:GSKMore) (formerly GlaxoSmithKline) recently made headlines with the world’s first RSV vaccine, but its forays into personalized medicine are even more exciting. The company has a long-term partnership with Tempus, a privately held company, to use its AI-enhanced platform to improve clinical trials and drug design. This will also allow access to anonymized patient data.

All this data is produced based on long-term partnerships with the following companies: 23 and me (Nasdaq:myself). In this partnership, GSK will receive both genomic data and direct patient health and life data. 23andMe is somewhat unique in the amount of non-genetic health data it successfully extracts from its many users. And receiving this data will enable GSK to better understand the interplay between patient health and the genome. This combination of genetic and patient data will enable GSK to better understand its drug targets.

Overall, GSK has an impressive drug pipeline, a wealth of genetic and patient data, and an AI-enhanced platform that makes this data available. This combination therefore allows the company to develop drugs and treatments that are specific to any of the myriad different ways the disease manifests itself.

GSK also makes great investments outside of its precision medicine activities. The income statement for the first quarter of 2023 shows revenue of $8.77 billion and net income of $2.04 billion. With dozens of drugs, more in development, and a strong position in medical big data, the company is one of the best personalized medicine stocks in the long run.

Adaptive Biotechnology (ADPT)

Photograph of test tubes and droplets with the visual effect of a purple and reddish orange sunset representing biotechnology

Source: shutterstock.com/Romix Image

Adaptive biotechnology (Nasdaq:ADPTMore) is named after the adaptive immune system, our body’s system that responds to disease. Their technology aims to harness the power of the immune system to treat various disorders and diseases. Adaptive’s flagship product is clonoSeq, which tracks leukemia left in patients after chemotherapy.

Adaptive Biotechnologies is currently small, but has strong ongoing collaborations that have led to great success.collaboration with them Roche Group (OTCMKTS:Ruby) has led to a pipeline of T-cell therapies against a variety of cancers and diseases. T-cell therapy is powerful because it harnesses the patient’s own immune system to fight disease. And it can be a more effective and far more targeted response than any drug or drug.

However, Adaptive Biotechnologies are still speculative. Earnings for the first quarter of 2023 were just $37 million in earnings and a net loss of just $58 million. Those numbers fell short of analyst expectations and led to a significant drop in the stock. But as far as speculative play is concerned, Adaptive uses some of the most fascinating technology available in medicine today. And since their immune systems can be programmed to fight any disease, the potential benefits of their technology are very high. As such, it remains a strong personalized medicine stock to hold for the future for investors willing to take risks.

As of the issue date, John Blankenhorn did not hold (directly or indirectly) any positions in the securities referenced in this article. The opinions expressed in this article are those of the author and are subject to InvestorPlace.com Publishing Guidelines.

John Blankenhorn is a neuroscientist at Emory University. He has extensive experience in biochemistry, biotechnology and pharmaceutical research.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *